Description
PrymaLab · Research use only
Preloaded Autoinjector | Sermorelin | 3ml Pen | 6mg
Sermorelin, GHRH(1-29) amide, ready in solution: 6 mg in a 3 mL pen
Sermorelin is the 29-residue N-terminal stretch of human growth hormone-releasing hormone, amidated at its C-terminus. This listing is a preloaded autoinjector pen holding 6 mg of the peptide already dissolved in a 3 mL cartridge, about 2 mg/mL, so there is no powder to reconstitute. Research on sermorelin covers growth hormone release from the pituitary and clinical work in children and older men, and a separate set of papers maps how GRF peptides break down in water.
Specifications
| Property | Value |
|---|---|
| Compound | Sermorelin GHRH(1–29)-NH₂; GRF(1–29) |
| CAS number | 86168-78-7 |
| Molecular formula | C149H246N44O42S |
| Theoretical mass | 3357.9 Da |
| Sequence / structure | H-YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH₂ (29 residues; C-terminal amide) |
| Contents | Sermorelin: 6 mg per 3 mL pen (0.2% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a 3 mL glass cartridge inside a preloaded autoinjector pen fitted with a needle |
| Storage, sealed | Store at 2–8 °C in the original carton, protected from light |
| Safety data sheet | PL-SDS-151 |
What is in the pen
The pen carries 6 mg of sermorelin in 3 mL of solution, which is 2 mg per mL. It is the same GHRH(1-29)-NH₂ that is sold freeze-dried in the Sermorelin 10 mg vial and the Sermorelin 5 mg vial, with the sequence and the 3357.9 Da theoretical mass shown in the specifications. Storage conditions are printed on the pen label. The concentration is fixed at filling, whereas a vial lets the laboratory choose its own volume of diluent. The general trade-offs between the two formats are set out in peptide pen vs vial.
Sermorelin in solution
A liquid format puts sermorelin in the state where it is least stable. Studies of GRF in water traced degradation to two sites: Asp3, which is cleaved from Ala4 in acid and isomerises above pH 4, and Asn8, which deamidates from about pH 5 upward; the peptide held up best between pH 4 and 51. Their temperature work ran from 22 to 55 °C, and between 22 and 37 °C the rate of Asn8 deamidation changed relatively little; refrigerator temperatures were not part of it1. In a related GRF analogue kept at neutral pH, the deamidated product lost 400 to 500-fold potency in pituitary cell assays2. Neither paper tested this pen’s solution, so they explain the chemistry rather than set a shelf life.
What the research covers
Sermorelin, a 29-amino-acid analogue of human GHRH, is the shortest synthetic peptide with the full biological activity of the native hormone, and it stimulates growth hormone secretion specifically from the anterior pituitary3. In clinical work it served as a rapid, fairly specific diagnostic test for growth hormone deficiency in children, with fewer false positives than other provocative tests, although a normal result could not exclude deficiency of hypothalamic origin3. As a growth treatment, in an open-label multicentre study of 110 prepubertal children with the deficiency, it raised mean height velocity from 4.1 to 8.0 cm a year over six months without excess IGF-I or changes in fasting glucose4. In ten healthy older men, two weeks of GHRH(1-29) brought 24-hour growth hormone output and IGF-I up to the levels of nine young men, with no change in fasting glucose or blood pressure5.
These were clinical studies in defined groups of people, and none tested a preloaded solution or any PrymaLab product. The full literature, including the diagnostic data and what the trials left unresolved, is in the sermorelin research guide.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. The certificate covers the peptide lot used to fill the pen, not the finished solution. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
How does the pen differ from the sermorelin vials?
The vials hold dry peptide that is stored at −20 °C and dissolved in the lab when needed, at whatever concentration the work calls for. The pen holds the same peptide already in solution at 2 mg/mL, so the concentration is fixed and the clock on solution stability starts at filling.
What does the certificate cover for the pen?
It covers the lot of sermorelin used to fill the pen, not the finished solution in the cartridge. The testing section on this page explains where published certificates are listed and how to check one by number and key.
Do the stability papers say how long the pen keeps?
No. They studied GRF peptides in buffers between 22 and 55 °C and show which residues degrade and at what pH. They did not test this solution or refrigerated storage, so follow the storage conditions on the pen label.
Is the pen intended for human use?
No. Like every PrymaLab product it is sold only for laboratory research. It is not approved for human or veterinary use, and nothing on this page should be read as a guide to using it in people or animals.
References
- Bongers J, Heimer EP, Lambros T, et al. Degradation of aspartic acid and asparagine residues in human growth hormone-releasing factor. Int J Pept Protein Res. 1992;39(4):364-74. DOI · PubMed
- Friedman AR, Ichhpurani AK, Brown DM, et al. Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Replacement of asparagine residues by serine stabilizes. Int J Pept Protein Res. 1991;37(1):14-20. DOI · PubMed
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. DOI · PubMed
- Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96. DOI · PubMed
- Corpas E, Harman SM, Piñeyro MA, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5. DOI · PubMed
Research use only
For laboratory research use only. This product is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Reviews
There are no reviews yet.